Teva Pharmaceuticals
TEVA
562 hedge funds and large institutions have $11B invested in Teva Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 197 increasing their positions, 186 reducing their positions, and 85 closing their positions.
40% more call options, than puts
Call options by funds: $515M | Put options by funds: $369M
3.56% more ownership
Funds ownership: 58.77% → 62.33% (+3.6%)
6% more repeat investments, than reductions
Existing positions increased: 197 | Existing positions reduced: 186
4% less funds holding
Funds holding: 584 → 562 (-22)
21% less first-time investments, than exits
New positions opened: 67 | Existing positions closed: 85
25% less capital invested
Capital invested by funds: $14.7B → $11B (-$3.71B)
28% less funds holding in top 10
Funds holding in top 10: 36 → 26 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$394M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$153M |
| 3 |
GCM
Glenview Capital Management
New York
|
+$113M |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$112M |
| 5 |
DFO
Duquesne Family Office
New York
|
+$105M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$154M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$114M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
-$93.5M |
| 4 |
MRCP
Maple Rock Capital Partners
Toronto,
Ontario, Canada
|
-$92.8M |
| 5 |
Morgan Stanley
New York
|
-$69.9M |
TEVA Hedge Fund Activity: Q1 2025 in Review
562 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2025, worth a combined $11B — down 25% from $14.7B a quarter earlier.
Sellers outnumbered buyers: 85 funds closed out of TEVA and 67 opened new positions — a net loss of 18 holders — while 186 trimmed existing stakes and 197 added.
The largest buyer was Harel Insurance Investments & Financial Services, adding an estimated $394M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $154M sold.
- 562 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2025, down from 584 in Q4 2024.
- Funds reported $11B of Teva Pharmaceuticals stock for Q1 2025, down 25% quarter-over-quarter.
- 67 funds opened new Teva Pharmaceuticals positions in Q1 2025 and 85 closed out, a net change of -18 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2025 was Harel Insurance Investments & Financial Services, an estimated $394M added.
- The largest Teva Pharmaceuticals seller in Q1 2025 was Arrowstreet Capital, an estimated $154M sold.
Based on aggregated 13F filings for Q1 2025.